Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Increases By 217.0%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 398,714 shares, an increase of 217.0% from the August 15th total of 125,762 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average trading volume of 3,391,068 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent quarter. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Stock Up 6.1%

Shares of NYSEAMERICAN VTAK traded up $0.01 during midday trading on Friday, hitting $0.17. 712,209 shares of the stock traded hands, compared to its average volume of 2,238,078. The company has a market cap of $2.52 million, a PE ratio of -0.03 and a beta of -1.03. Catheter Precision has a one year low of $0.16 and a one year high of $3.20. The business has a 50 day moving average price of $0.36 and a two-hundred day moving average price of $0.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its earnings results on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.The company had revenue of $1.02 million for the quarter, compared to analysts’ expectations of $2.00 million.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.